Transforming growth factor-beta (TGF-beta) is a growth modulator that inhibits the proliferation of many epithelial cells through interaction with its receptors, the type I and type II receptors (TGF-beta RI and RII) by activating their serine/threonine kinase activities. Loss of growth inhibition b
Nkx2.1 transcription factor in lung cells and a transforming growth factor-β1 heterozygous mouse model of lung carcinogenesis
✍ Scribed by Yang Kang; Haroun Hebron; Laurent Ozbun; Jennifer Mariano; Parviz Minoo; Sonia B. Jakowlew
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 602 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20034
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The Nkx2.1 homeobox gene and transforming growth factor‐β1 (TGF‐β1) are essential for organogenesis and differentiation of the mouse lung. NKX2.1 is a marker of human lung carcinomas, but it is not known whether this gene participates in early tumorigenesis. Addition of TGF‐β1 to TGF‐β1‐responsive nontumorigenic mouse lung cells cotransfected with a NKX2.1Luc luciferase reporter and either a Sp1 or Sp3 plasmid showed a significant increase or decrease, respectively, in NKX2.1Luc transcription. Cotransfection of Sp3 and dominant‐negative TGF‐β type II receptor plasmids negated the effect of Sp1. Cotransfected Sp1 plasmid with either dominant‐negative Smad2 or Smad3 or Smad4 plasmids significantly decreased NKX2.1Luc transcription. Electrophoretic mobility shift assays revealed binding of Sp1 and Smad4 to the NKX2.1 promoter. With a TGF‐β1 heterozygous mouse model, Nkx2.1 mRNA and protein in lungs of TGF‐β1 heterozygous mice were significantly lower compared to wildtype (WT) littermates. Competitive reverse transcription (RT)‐polymerase chain reaction (PCR) and immunostaining showed that Nkx2.1 mRNA and protein decreased significantly in adenomas and adenocarcinomas compared to normal lung tissue. Our in vitro data showed that regulation of Nkx2.1 by TGF‐β1 occurs through TGF‐β type II receptor and Smad signaling, with Sp1 and Sp3 in lung cells. Our in vivo data showed reduced Nkx2.1 in lungs of TGF‐β1 heterozygous mice compared to WT mice, that is detectable in adenomas, and that is further reduced in carcinogenesis, and that correlates with reduction of Sp1, Sp3, and Smads in lung adenocarcinomas. Our findings suggest that reduced Nkx2.1 and TGF‐β1 signaling components may contribute to tumorigenesis in the lungs of TGF‐β1 heterozygous mice. Published 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Transforming growth factor (TGF)‐β1, whose gene is located on mouse chromosome 7, has been proposed to be involved in skin carcinogenesis. In the study presented here, we demonstrated that single topical treatments with different types of tumor promoters, i.e., the protein kinase C acti
To elucidate the role of transforming growth factor-beta1 (TGF-beta1) and the TGF-beta type II receptor (TGF-beta RII) as tumor-suppressor genes in lung carcinogenesis, we mated C57BL/6 mice heterozygous (HT) for deletion of the TGF-beta1 gene with A/J mice to produce AJBL6 TGF-beta1 HT progeny and
Hepatocyte growth factor, a potent hepatocyte mitogen in vitro, appears to trigger hepatocyte regeneration after partial hepatectomy and after acute liver cell netcrosis. Transforming growth factor-a and transforming growth factor+, may also be involved in the control of liver regeneration. In this
In memoriam to the late Philippe Vigier , Emeritus Head of the Department of Retrovirology, Institut Curie. In wartime he fought for the freedom of his country, in peacetime for the elucidation of cancer.